

CURRICULUM VITAE*JOSEPH M. CONEY, MD, FACS, FASRS*

OFFICE ADDRESSES Retina Associates of Cleveland, Inc.
690 White Pond Drive, Suite 120; Akron, Ohio 44320
24075 Commerce Park; Cleveland, Ohio 44122
4690 Munson Street NW; Canton, Ohio 44718
15299 Bagley Road, Suite 200; Cleveland, Ohio 44130
1350 Portage Trail; Cuyahoga Falls, Ohio 44223
340 Oxford Street, Suite 210; Dover, Ohio 44622
6100 South Broadway Avenue, Suite 200; Lorain, Ohio 44052
3591 Reserve Commons Drive; Medina, Ohio 44256
9485 Mentor Avenue, Suite 110; Mentor, Ohio 44060
17534 Royalton Road, Suite 201; Strongsville, Ohio 44136
170 North Road NE; Warren, Ohio 44483
4350 Crocker Road, Suite 200; Westlake, Ohio 44145
5390 Belmont Avenue; Youngstown, Ohio 44505

TELEPHONE 216-831-5700

WEBSITE www.retina-doctors.com

EDUCATION

College University of Illinois
Champaign, Illinois
1990–1994, BS (Biology)

Medical School Loyola-Stritch School of Medicine
Maywood, Illinois
1995–1999, MD

POSTGRADUATE TRAINING

Internship Transitional
Resurrection Medical Center
Chicago, Illinois
1999–2000

Residency Ophthalmology
Case Western Reserve University
Cleveland, Ohio
2000–2003

Fellowships

Medical Retina Fellowship
 Joslin Diabetes Center—an affiliate of Harvard Medical School
 Boston, Massachusetts
 2003–2004
 Surgical Retina Fellowship (2 years) Vitreoretinal Foundation
 Memphis, Tennessee
 2004–2006

LICENSURE AND BOARD CERTIFICATION

Licensed to practice medicine in Ohio and Pennsylvania

Fellow of the American College of Surgeons, 2021

Fellow of the American Society of Retina Specialists

Diplomate, American Board of Ophthalmology, 2006; passed Maintenance of Certification, 2017

PROFESSIONAL POSITIONS

Retina Associates of Cleveland, 2006–

Private practice in vitreoretinal surgery and diseases. Associates: Lawrence J. Singerman, MD; Michael A. Novak, MD; Scott D. Pendergast, MD; David G. Miller, MD; Jerome P. Schartman, MD; Llewelyn J. Rao, MD; Arnold F. Nothnagel, DO; Shawn A. Lewis, MD; Sean M. Platt, MD, MBA; Hang Pham, MD, Thomas P. Hull, MD, Thomas J. Tsai, MD; Shawn C. Wilker, MD; Ledian Goduni, MD

National Medical Association

Rabb Venable Program Chair, 2025
 Executive Committee Member, 2005–
 Board of Directors, Ophthalmology Section, 2005–
 Postgraduate Section liaison, 2005–
 President, Ophthalmology Section, 2013–2015
 President-elect, Ophthalmology Section, 2011–2013
 Councilor to the American Academy of Ophthalmology Council, 2009–2013
 Chair, Retina Section, 2009–2012
 Secretary, Ophthalmology Section, 2005–2012
 Service Award, 2006

American Academy of Ophthalmology

Surgical Scope Fund Committee, 2025-
 Leadership Development Program-LDP XXVI, Class of 2025
 Deputy Section Leader, 2025-
 Surgical Scope Fund Committee, 2025-
 Council Advisory Recommendation Workgroup, 2024-
 Academy's Awards Committee, 2024-

American Academy of Ophthalmology (cont'd)

Nominating Committee of the State Section of the Council, 2023-
Councilor, 2022-
LEO Award, 2022
Special Recognition Award, 2013, 2022
Achievement Award, 2019
Mentor, American Academy of Ophthalmology/Associate of University Professors of
Ophthalmology (AAO/AUPO) Minority Ophthalmology Mentoring Program 2017-
Member, Knowledge Base Subcommittee - Retina/Vitreous Panel, 2013
Selected participant, Leadership Development Program (LDP X), 2007–2008
Project: National Medical Association Health Fair and Eye Care America Initiative
Member, 2000-

American Board of Ophthalmology

Volunteer Oral Examiner, 2022-

Ohio Ophthalmological Society

Councilor, 2022-
President, 2018–2020
Vice President, 2016–2018
Secretary/Treasurer, 2014–2016
Advocacy Day, 2012-
Board of Directors, District 5 Representative, 2012–
Member, 2006-

Alimera Sciences (ANI Pharmaceuticals, Sept 2024)

Iluvien Speakers Bureau, 2022-2024
Speakers' Bureau, 2017–2024
Clinical Advisory Board, 2016-2024

Allergan/AbbVie

Health Equity Advisory Committee, 2020-
Speakers' Bureau, 2017–
US Retina Regional Scientific Advisory Board, 2012–
Clinical Advisory Board, 2010–

American Eye Study Club

Emeritus 2022-
Member 2010-

American Society of Retina Specialists

Advisory Hoc Committee on Diversity and Inclusion, 2020
Underrepresented in Retina Mentorship Program, 2022-
Member, 2007-

Apellis

Patient Ambassador Program, 2024-

Clinical Advisory Board, 2022-
Speakers Bureau, 2019-

Blackdoctor.org

Medical Advisory Board 2023-
Featured Retina Specialist Expert, 2022-2023

British Journal of Ophthalmology

Manuscript reviewer, 2022-

Bryn Mawr Communications

Guest Medical Editor, 2021-
OcuTerra Advisory Board, 2022-2024

Cleveland Ophthalmological Society

President, 2014–2015
President-elect, 2013–2014
Vice-president, 2012–2013
Secretary, 2011–2012

Diabetes Partnership of Cleveland (formerly *Diabetes Association of Greater Cleveland*) (closed 2017)

Co-chair, Program Committee, 2013–2017
Board of Directors, 2006–2017

Eyeteck Inc.

Clinical Advisory Board, 2008–2010

Genentech

Scientific Collaborator, 2025-
Patient Navigation Advisory Board, 2024-
Global Advisory Board, 2022
Elevatum Clinical Program, 2022-
Ophthalmology Advisory Board, 2020-
Faricimab Advisory Board, 2021-
Advancing Inclusive Research Steering Committee, 2018–
Lucentis Business Strategy National Advisory Board, 2012–
Retina Specialist Speakers Bureau, 2012–

Iveric Bio/Astellas

Izervay Speakers Bureau, 2023-2024

Journal of VitreoRetinal Diseases

Peer Reviewer, 2024-

Mediterranean Eye Society

Secretary, 2017–
Board of Directors 2016–

Med Learning Group

PeerView Program Chair CME Program, 2025
Program Chair, Vision RELIEF, 2022-1024

National Institutes of Health

Ambassador

National Medical Fellowships

National Committee Member, 2020-
Ad Hoc Diversity and Inclusion Ad Board, 2020-
McDonogh Committee Member, 2020-

Notal Vision

Speakers' Bureau, 2017–2020
Clinical Advisory Board, 2017–2020

Novartis

Clinical Trials Video Series, 2022-2023
Advisory Board, 2021-
Medical Advisory Board for EAGLE, 2021
Speakers' Bureau, 2019-2023
Beovu Speakers' Bureau, 2020

Paradigm

Program Chair, 2025
Steering Committee, 2022
Faculty Instructor, 2022, 2025
Teacher, 2022, 2025
Planner, 2022

Pasteur Club of NE Ohio

Executive Board Member, 2021-2023
President elect, 2021-2022

Regeneron

Eylea Commercial Steering Ad Board
Diversity, Equity, and Inclusion Team
Commercial Steering Committee, 2017–
Speakers Bureau, 2017-

Regenxbio

Consultant, 2021-

Retina Surgery Training in Haiti

Skills transfer initiative, 2016, 2017, 2018

Retina World Congress

Equity, Diversity and Inclusion Committee, 2020

RevHealth

Consultant, 2020

Thrombogenics

Regional Council on Ocriplasmin, 2013–2015

ACADEMIC APPOINTMENTS

Senior Clinical Instructor, Department of Ophthalmology and Visual Sciences, Case Western Reserve University School of Medicine/University Hospitals of Cleveland, Cleveland, Ohio, November 2008–

OTHER ACADEMIC AND ADMINISTRATIVE POSITIONS

Guest Editor, 2022-

Retina Today, March 2022 Issue

Program Chair, 2021-

Vision: RELIEF, Med Learning Group Regeneron grant

Resident Mentor, 2003–2004

Massachusetts General Hospital

Mentor Coordinator, 1996

Robert Wood-Johnson Foundation, Minority Medical Education Program

Inter-Fraternal Greek Council, 1993–1995

Board of Fraternity Affairs, University of Illinois at Urbana-Champaign

Chapter President (Polmarch), 1992–1994

Kappa Alpha Psi Fraternity, University of Illinois at Urbana-Champaign

Minority Organization for Pre-Health Students, 1992–1994

University of Illinois at Urbana-Champaign

Chapter President, 1993–1994

Chapter Treasurer, 1992–1993

PROFESSIONAL SOCIETIES AND COMMITTEES

*Sigma Pi Phi Fraternity Tau Boule, 2022-**Evolve Medical Education, 2020-**Vit-Buckle Society, 2013–*

American Retinal Detachment Society, 2011-
Roman-Barns Society of Ophthalmology, 2007–
Ohio State Medical Association, 2007–
Academy of Medicine of Cleveland and Northern Ohio, 2007–
Diabetes Association of Greater Cleveland, 2007–
Cleveland Ophthalmologic Society, 2000–2003, 2006–
Endocrine Society, 2002–
United States Boxing Federation Fight Doctor, 2001-2006
Cook County Physicians Association, 1996–2001
American Medical Association, 1996–

PROFESSIONAL SOCIETIES AND COMMITTEES (cont'd)

Student National Medical Association, 1995–1999
Chairman of National Convention, 1997–1998
Member Board of Directors, 1997–1998
Local Chapter President, 1997–1998
Local Chapter, Treasurer 1995–1996
National Delegate, 1995–1999
Region II Delegate, 1995, 1996, 1999
Region II Fundraiser Coordinator, 1996–1997

Medical Student Union Representative, 1995–1999
Loyola-Stritch School of Medicine

Primary Care Committee Chair, 1995
American Medical Student Association

University of Illinois Alumni Association, 1995–

Kappa Alpha Psi Fraternity Inc., 1992–

HONORS AND AWARDS

Business Rate Youngstown Best of 2024-
American Eye Study Club, Axel Hansen Distinguished Lecture Award, 2024
Brandon Hall Group Gold Excellence Award, 2023
Journal of Vitreoretinal Diseases Distinguished Contributor Award, 2023

American Eye Study Club Emeritus Award, 2022

American Eye Study Club, Killian Award, 2022

Best of Cleveland Awards – Doctors, 2019,2022-

Vitals Honoree Compassionate Doctor, 2021-

Best of Cleveland Awards – Doctors, 2019-

America's Most Honored Professionals – Top 1%, 2018

Best Doctors in America, 2017–2020

Castle Connolly Top Doctors Award, 2015–

Top Doctors in Ohio Award, 2017-

Vitals Compassionate Doctor Award, 2018, 2020, 2021-

Vitals On-Time Doctor Award, 2018, 2020

Vitals Patients' Choice Award, 2014–2016, 2018, 2020-

Fox8 News, Featured for Black History Month 2017, 2023

Eagle Award for Service and Dedication, 2015

National Medical Association, Philadelphia, Pennsylvania

Special Recognition Award, 2013, 2022
American Academy of Ophthalmology Leadership Development Program

Service Award, 2011, 2013
National Medical Association, Toronto, Ontario, Canada

America's Top Ophthalmologists, Consumers Research Council of America, 2007

Cambridge Who's Who of Executives and Professionals, Honored Lifetime Member, 2007-

Rabb-Venable Award for Outstanding Fellow Research Presentation, 2004
National Medical Association; San Diego, California

Rabb-Venable Award for Outstanding Resident Research Presentation, 2003
National Medical Association; Philadelphia, Pennsylvania

Outstanding Resident Research Award, 2003
Case Western Reserve University; Cleveland, Ohio

Janice Douglas-David Satcher Clerkship, 1999
Case Western Reserve University; Cleveland, Ohio

National Merit Award, 1995
Student National Medical Association

Member of the Year, 1995
Student National Medical Association

Cook County Physicians Association Scholarship Recipient, 1995
Chicago, Illinois

Dean's List, College of Liberal Arts & Science, 1990–1993
University of Illinois; Champaign, Illinois

Delta Sigma Theta Scholarship Recipient, 1991

Alpha Lambda Delta National Honor Society, 1990
University of Illinois; Champaign, Illinois

Phi Eta Sigma Freshman Honor Society, 1990
University of Illinois, Champaign, Illinois

HOSPITAL & ASC AFFILIATIONS

Cleveland Eye & Laser Surgery Center, Fairview, Ohio
Brainard Surgery Center; Cleveland, Ohio
University Hospitals of Cleveland; Cleveland, Ohio
Summa Health; Akron, Ohio
Lippy Surgery Center; Warren, Ohio

SHORT-TERM MEDICAL MISSIONS

Skills Transfer Initiative, in conjunction with Surgical Eye Expeditions [SEE] International;
Port-au-Prince, Haiti; 2015–2018

Elective rotation, Aravind Eye Hospital, Department of Ophthalmology; Maduri, India;
May-June 2004

RESEARCH ACTIVITIES

NIH-funded Grants

DRCRnet Protocol AB. Intravitreal anti-VEGF vs. prompt vitrectomy for vitreous hemorrhage from proliferative diabetic retinopathy
Principal Investigator, 2017-

DRCRnet Protocol AG. Randomized clinical trial assessing the effects of pneumatic vitreolysis on vitreomacular traction
Co-investigator, 2019–2020

DRCRnet Protocol AH. Single-arm study assessing the effects of pneumatic vitreolysis on macular hole
Co-investigator, 2019–2020

DRCRnet Protocol W. Intravitreal anti-vascular endothelial growth factor treatment for prevention of vision threatening diabetic retinopathy in eyes at high risk
Co-investigator, 2017–2022

DRCRnet Protocol V. Treatment for central involved diabetic macular edema in eyes with very good visual acuity
Co-investigator, 2014–2018

DRCRnet Protocol U. Short-term evaluation of combination corticosteroid+anti-VEGF treatment for persistent central-involved diabetic macular edema following anti-VEGF therapy in pseudophakic eyes
Co-investigator, 2014–2017

*Study of **CO**mparative Treatments for **RE**tinal Vein Occlusion 2 (SCORE2)*
Co-investigator, 2014–2016

DRCRnet Protocol S. Prompt panretinal photocoagulation versus intravitreal ranibizumab with deferred panretinal photocoagulation for proliferative diabetic retinopathy
Co-investigator, 2012–2017

DRCRnet Genes in Diabetic Retinopathy Project
Co-investigator, 2012–

DRCRnet Protocol T. Comparative effectiveness study of intravitreal aflibercept, bevacizumab, and ranibizumab for diabetic macular edema
Co-investigator, 2012–2018

Home vision monitoring in AREDS2 for progression to neovascular AMD using the ForeseeHome device
Co-investigator, 2011–2013

DRCRnet Protocol M. Effect of diabetes education during retinal ophthalmology visits on diabetes control
Co-investigator, 2011–2015

DRCRnet Protocol R. Phase II evaluation of topical NSAIDS on eyes with non-central involved DME
Co-investigator, 2011–2013

DRCRnet Protocol N. Evaluation of intravitreal ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy
Co-investigator, 2010–2012

DRCRnet Protocol O. Comparison of time-domain OCT and spectral domain OCT retinal thickness measurement in diabetic macular edema

Co-investigator, 2009–2010

Comparison of age-related macular degeneration treatments trials: Lucentis-Avastin trial (CATT)

Co-investigator, 2008–2012

DRCRnet Protocol I. Intravitreal ranibizumab or triamcinolone acetonide in combination with laser photocoagulation for diabetic macular edema

Co-investigator, 2007–2014

DRCRnet Protocol K. Course of response to focal photocoagulation for diabetic macular edema

Co-investigator, 2007–2008

Age-Related Eye Disease Study (AREDS) 2

Co-investigator, 2006–2012

*Standard Care vs. **C**orticosteroid for **R**etinal Vein Occlusion (SCORE) Study*

Co-investigator, 2006–2009

Other National Clinical Trials

A phase III, randomized, double-masked, active-controlled trial of a single intravitreal injection of 4D-150 in adults with macular neovascularization secondary to age-related macular degeneration.

(4FRONT-1)

Principal Investigator, 2025-

Phase II/III, A randomized, double-masked multi-center 3-Arm pivotal phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal EYE103 Compared with Intravitreal Ranibizumab (0.5mg) in Participants with Diabetic Macular Edema (BRUNELLO)

Principal Investigator, 2024-

Phase III, A randomized, double-masked, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with treatment Naïve Neovascular Age-Related Macular Degeneration (Ocular Therapeutix SOL)

Principal Investigator, 2024-

Phase II, A Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Treatment Effect of Intravitreal AVD-104 in Participants with Geographic Atrophy Secondary to Age-related Macular Degeneration (SIGLEC)

Principal Investigator, 2024-

Phase IV, A Prospective, Multicenter, Open-label, Observational Study to Evaluate Real-world Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (SYFOVRE) in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (GARLAND)

Principal Investigator, 2023-

Phase III, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD) (COAST)

Principal Investigator, 2023-

A phase IV, multicenter, open-label, single-arm study designed to investigate treatment response in treatment-naïve, underrepresented (Black/African American, Hispanic/Latino American, or Native American/Alaskan Hawaiian or other Pacific Islander) adult patients with diabetic macular edema (DME) who are treated with Faricimab (6mg). (GENENTECH/ELEVATUM)

Principal Investigator, 2022-

A prospective, randomized double-masked, phase 2 study to evaluate the safety and efficacy of OTT166 eye drops for treatment naïve, moderately severe to severe nonproliferative diabetic retinopathy or mild nonproliferative diabetic retinopathy. (OCUTERRA/DREAM)

Principal Investigator, 2022-

Phase III, A randomized, partially masked, controlled clinical study to evaluate the efficacy and safety of RGX-314 gene therapy in participants with nAMD (ASCENT)

Principal Investigator, 2022-

Phase IIb/III, A randomized, partially masked, controlled, clinical study to evaluate the efficacy and safety of RGX-314 gene therapy in participants with nAMD (ATMOSPHERE)

Principal Investigator, 2021-

Phase III, A prospective, randomized, double-masked, active comparator-controlled, multicenter, two-arm study to evaluate the efficacy and safety of intravitreal KSI-301 compared with intravitreal aflibercept in participants with neovascular (wet) age-related macular degeneration 9=(wAMD) (DAYLIGHT)

Principal Investigator, 2021-2023

Phase III, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan in subjects with geographic atrophy secondary to age-related macular degeneration (AMD) (GALE)

Principal Investigator, 2021-

Phase III, A 96-week, two-arm, randomized, single-masked, multi-center study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy (CONDOR)

Principal Investigator, 2021-2023

Phase IV, A randomized, masked, controlled study of intravitreal ILUVIEN® implant as baseline therapy in patients with early diabetic macular edema (NEW DAY).

Principal Investigator, 2020 -2025

Phase III, An Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multicenter Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion (RAPTOR CRTH258C2301)

Principal Investigator, 2019-2021

Phase III, A multicenter, sham-controlled, randomized, double-masked study assessing the efficacy and safety of intravitreal injects of 44 microns DE-109 for the treatment of active, non-infectious uveitis of the posterior segment (LUMINA)

Principal Investigator 2019-2022

Phase III, Randomized double-masked, sham controlled study to compare APL-s VS sham in patients with GA secondary to AMD (Apellis-Derby)

Principal Investigator, 2019-2021

Phase II, randomized, placebo-controlled, double-masked study to assess safety and efficacy of multiple doses of IONIS-FB-LRX, an Antisense Inhibitor of complement factor B in patients with GA secondary to AMD (IONIS/ISIS)

Principal Investigator, 2019-2023

Phase IIa masked study of OPT-302, a VEGF-C and VEGF-D inhibitor, in combination with aflibercept for persistent central-involved DME. (Opthea)

Principal Investigator, 2019-2020

Eighteen-month, two-arm, randomized, double masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (Raptor)

Principal Investigator, 2019–2021

Eighteen-month, two-arm, randomized, double masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to macular edema secondary to central retinal vein occlusion (Raven)

Principal Investigator, 2019–2021

Phase III, multicenter, double-masked, randomized, dose-ranging trial to evaluate the efficacy and safety of conbercept intravitreal injection in subjects with neovascular age-related macular degeneration (AMD) (PANDA)

Principal Investigator, 2019–2021

Phase 2 double-masked, placebo-controlled study to assess the safety and efficacy of subcutaneously administered AKB-9778 15 mg once daily or 15 mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy (TIME-2b study)

Principal Investigator, 2017–2019

Phase III double-masked study of safety and efficacy of abicipar pegol in patients with neovascular age-related macular degeneration (CEDAR)

Principal Investigator, 2015–2019

Efficacy and safety study of squalamine ophthalmic solution in subjects with neovascular AMD (MAKO)

Principal Investigator, 2016–2017

Randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration (APEX)

Principal Investigator, 2016–2018

A 2-year, multicenter, randomized, controlled, masked, dose-finding trial to assess the safety and efficacy of multiple intravitreal injections of AGN211745 (small interfering RNA) in subjects with subfoveal CNV secondary to AMD (SIRIUS)

Principal investigator, 2006–2008

Phase II, multicenter, open-label extension study to evaluate the long-term safety and tolerability of intravitreal injections of FJTR2163 in patients with geographic atrophy secondary to age-related macular degeneration (GALLEGO-OLE)

Co-Investigator, 2022

Phase III, A prospective, randomized, double-masked, sham-controlled, multicenter, two-arm study to evaluate the efficacy and safety and intravitreal SKI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) (GLOW)

Co-Investigator, 2022-2023

Phase II/III, A randomized, double masked, active-controlled study for the efficacy and safety of high-dose aflibercept in patients with diabetic macular edema (DME) (PHOTON)

Co-Investigator, 2020-

Phase II, randomized, multicenter study to assess the dose level of the multiple THR-149 injections and to evaluate the efficacy and safety of THR-149 versus aflibercept for the treatment of diabetic macular edema (DME) (KALAHARI)

Co-Investigator, 2020-2023

Phase II, multicenter, randomized double-masked, sham-controlled study of the safety and efficacy of intravitreal injections of NGM621 in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) (CATALINA)

Co-Investigator, 2020-2022

Phase III, A prospective, randomized, double-masked, active comparator-controlled, multicenter, to-arm study to evaluate the efficacy and safety of intravitreal KSI-301 compared with intravitreal aflibercept in participants with visual impairment due to treatment-naïve macular edema secondary to retinal vein occlusion (BEACON)

Co-Investigator, 2020-2022

Phase III, A multicenter, open-label extension study to evaluate the long-term safety and tolerability of faricimab in patients with neovascular age-related macular degeneration (rolled over from parent study GR 40844 LUCERNE) (AVONELLE-X)

Co-Investigator, 2020-2024

Phase III, multicenter, open label extension study to evaluate the long-term safety and tolerability of faricimab in patients with diabetic macular edema (rolled over from YOSEMITE) GR41987 (RHONE-X)

Co-Investigator, 2020-2023

Phase II/III multicenter, randomized, double-masked, parallel-group, placebo-controlled study to investigate the safety, pharmacokinetics, tolerability, and efficacy of oral ALK001 in geographic atrophy secondary to AMD (SAGA)

Co-investigator, 2019–2023

Phase II, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with nAMD (LUCERNE)

Co-investigator, 2019–2020

Phase III, multicenter, randomized, double-masked study to assess the safety and efficacy of brolocizumab vs. aflibercept in nAMD with persistent retinal fluid (MERLIN)

Co-investigator, 2019–2021

Phase III, randomized, double-masked, multicenter, controlled study to evaluate the efficacy and safety of brolocizumab in treatment of patients with visual impairment due to diabetic macular edema (KESTREL)

Co-investigator, 2019–2021

Phase III, A 24 week, double-masked, multicenter, two arm extension study to collect safety and efficacy data on brolocizumab 6 mg drug product intended for commercialization in patients with neovascular age-related macular degeneration who have completed the CRTH258A2301 study

Co-Investigator, 2018-2019

Phase III, multicenter, double-masked, randomized, dose-ranging trial to evaluate the efficacy and safety of conbercept intravitreal injection in subjects with neovascular age-related macular degeneration (PANDA I)

Co-investigator, 2018–2021

Phase III randomized, double-masked, parallel group, multicenter study to compare the efficacy, safety, pharmacokinetics and immunogenicity between SB11 and Lucentis in subjects with neovascular age-related macular degeneration

Co-investigator, 2018–2019

Phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema (YOSEMITE)

Co-investigator, 2018–2021

Phase 2b randomized, double-masked, controlled trial to assess the safety and efficacy of intravitreal administration of Zimura™ (anti-c5 aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration

Co-investigator, 2018–2020

Phase III randomized, double-masked, parallel group, multicenter study to compare the efficacy, safety, pharmacokinetics and immunogenicity between SB11 and Lucentis in subjects with neovascular age-related macular degeneration

Co-investigator, 2018–2019

Phase III multicenter randomized, sham controlled, study to determine the safety and efficacy of Renexus® in macular telangiectasia type 2 (NTMT-03-A)

Co-investigator, 2017–2022

Phase II, multicenter, randomized, single-masked, sham-controlled study of safety, tolerability and evidence of activity of intravitreal APL-2 therapy in patients with geographic atrophy (GA)

Co-investigator, 2015–2018

Randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration

Co-investigator, 2015–2018

Phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration (PROXIMA)

Co-investigator, 2015–2018

Phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anti PDGF-B pegylated aptamer) administered in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy in subjects with subfoveal neovascular age-related macular degeneration

Co-investigator, 2015–2017

An 18-month Phase 2a open label, randomized study of Avastin, Lucentis, or Eylea (anti-VEGF therapy) administered in combination with Fovista (anti-PDGF BB pegylated aptamer)

Co-investigator, 2015–2017

A study of lampalizumab intravitreal injections administered every two weeks or every four weeks to patients with geographic atrophy (EXPOSURE)

Co-investigator, 2015–2017

LHA510 proof-of-concept study as a maintenance therapy for patients with wet age-related macular degeneration

Co-investigator, 2015–2016

A study investigating the efficacy and safety of lampalizumab intravitreal injections in patients with geographic atrophy secondary to age-related macular degeneration (CHROMA)

Co-investigator, 2014–2017

Phase 2, multi-center study to compare the efficacy and safety of a chemokine CCR2/5 receptor antagonist with ranibizumab in adults with diabetic macular edema
Co-investigator, 2014–2015

Phase 2 multicenter randomized clinical trial of ciliary neurotrophic factor (CNTF) for macular telangiectasia type 2 (Mactel CNTF 2)
Co-investigator, 2013–2017

Phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anti PDGF-B pegylated aptamer) administered in combination with Lucentis compared to Lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration
Co-investigator, 2013–2017

Phase 2b/3 multicenter, randomized, double-masked, dose-ranging study comparing the efficacy and safety of emixustat hydrochloride (ACU-4429) with placebo for the treatment of geographic atrophy associated with dry age-related macular degeneration (SEATTLE)
Co-investigator, 2013–2016

Prospective, two-cohort, single-masked study to evaluate the effect of ESBA1008 applied by microvolume injection or infusion in subjects with exudative age-related macular degeneration
Co-investigator, 2013–2015

Prospective, randomized, double-masked, multicenter, two arm study comparing the efficacy and safety of ESBA1008 versus Eylea® in subjects with exudative age-related macular degeneration
Co-investigator, 2013–2014

Efficacy and safety of squalamine lactate eye drops in subjects with neovascular (wet) age-related macular degeneration
Co-investigator, 2012–2015

Safety and efficacy study of gevokizumab to treat active non-infectious uveitis (EYEGUARD™-A)
Co-investigator, 2012–2015

Safety and efficacy study of gevokizumab to treat non-infectious uveitis controlled with systemic treatment (EYEGUARD™-C)
Co-investigator, 2012–2015

Ocriplasmin for treatment for symptomatic vitreomacular adhesion including macular hole (OASIS)
Co-investigator, 2012–2014

Safety and tolerability of intravenous LFG316 in wet age-related macular degeneration
Co-investigator, 2012–2013

Single and repeat dose study of the safety and efficacy of AGN-150998 in patients with exudative age-related macular degeneration

Co-investigator, 2011-2014

A multicenter, randomized, sham-control, proof-of-concept study of intravitreal LFG316 in patients with geographic atrophy associated with age-related macular degeneration

Co-investigator, 2012-2015

Phase I multicenter open-label safety and tolerability clinical trial of ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia Type 2 (Mactel)

Co-investigator, 2011–2016

A study of safety, tolerability, and evidence of activity of FCFD4514S administered monthly or every other month to patients with geographic atrophy (Genentech)

Co-investigator, 2011–2013

Multicenter, double-masked, parallel group, placebo-controlled study to assess the efficacy and safety of voclosporin as therapy in subjects with active noninfectious intermediate, posterior, or pan-uveitis

Co-investigator, 2011–2013

Multicenter, 2 stage (open label, dose escalation, followed by masked, randomized) single dose study of the safety and efficacy of AGN-208397 in patients with macular edema (ME) associated with retinal vein occlusion (RVO)

Co-investigator, 2011–2012

Phase 2b dose-ranging study of pazopanib eye drops versus ranibizumab intravitreal injections for the treatment of neovascular age-related macular degeneration

Co-investigator, 2010–2011

Phase II, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) given in combination with Lucentis in subjects with neovascular age related macular edema (Ophthotech 1001)

Co-investigator, 2010–2011

Impact of Lucentis on psychological morbidity in patients with macular edema and neovascularization secondary to retinal vein occlusion

Co-investigator, 2009–2012

Phase III, double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5 mg and 2.0 mg ranibizumab administered monthly or on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration (HARBOR) (Genentech)

Co-investigator, 2009–2012

Geographic Atrophy Treatment Evaluation (GATE) Study

Co-investigator, 2009–2012

Phase Ia, multicenter, open-label, single-dose, dose-escalation study of the safety, tolerability, pharmacokinetics, and immunogenicity of intravitreal injections of FCFD4514S in patients with geographic atrophy

Co-investigator, 2009–2010

Phase II, randomized, double-masked, placebo-controlled, add-on study to assess the efficacy of oral aliskiren 300 mg one daily for diabetic macular edema

Co-investigator, 2009–2010

Phase I, single ascending dose and parallel group trial to establish the safety, tolerability, and pharmacokinetic profile of multiple intravitreal injections of Volociximab ($\alpha 5\beta 1$ integrin antagonist) as monotherapy or given in combination with Lucentis 0.5mg/eye in subjects with neovascular AMD (Ophthotech 3000)

Co-investigator, 2008–2012

Randomized, placebo controlled, double-masked, multicenter trial of microplasmin intravitreal injection for non-surgical treatment of focal vitreomacular adhesion

Co-investigator, 2008–2010

Phase 2, randomized, double-masked, placebo-controlled, dose-ranging clinical study to assess the safety and efficacy of subconjunctival injections of sirolimus in patients with DME secondary to diabetic retinopathy

Co-investigator, 2008–2010

Natural History of Geographic Atrophy Progression (GAP) Study

Co-investigator, 2008–2009

A study of ranibizumab injection in subjects with clinically significant macular edema center involvement secondary to diabetes mellitus (RIDE)

Co-investigator, 2007–2012

A masked, multicenter, randomized, controlled trial to assess the safety and efficacy of 700 μ g dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse diabetic macular edema

Co-investigator, 2007–2010

Indocyanine green (ICG) angiographic evaluation of ranibizumab (Lucentis®) treatment of pigment epithelial detachment (PED) associated with age-related macular degeneration (AMD)

Co-investigator, 2007–2009

OMEGA: a randomized, double-masked, dose-ranging, multi-center, Phase II study comparing the safety and efficacy of OT-551 with placebo to treat geographic atrophy associated with age-related macular degeneration

Co-investigator, 2007–2009

Sirion Phase II randomized, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in age-related macular degeneration

Co-investigator, 2007–2010

Age-related Macular Degeneration: Detection of Onset of new Choroidal neovascularization (AMD DOC): Comparison of PHP (Preferential Hyperacuity Perimetry) with supervised Amsler grid in detecting neovascular AMD in eyes at high risk for CNV

Co-investigator, 2007–2009

Phase I, single ascending dose trial to establish the safety, tolerability, and pharmacokinetic profile of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) monotherapy and of E10030 given in combination with Lucentis 0.3mg/eye in subjects with neovascular AMD (Ophthotech 1000)

Co-investigator, 2007–2008

A multicenter, randomized, placebo-controlled, double-masked, parallel group, dose-ranging clinical trial of intravitreal microplasmin in patients undergoing surgical vitrectomy: The MIVI III (Microplasmin for Vitreous Injection III) Trial

Co-investigator, 2007–2008

COBALT: COmbining Bevasiranib And Lucentis Therapy. A phase III, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis®, compared with Lucentis® monotherapy every 4 weeks in patients with exudative age-related macular degeneration (AMD)

Co-investigator, 2007–2008

Denali: a 24-month randomized, double-masked, controlled, multicenter, phase IIIB study assessing safety and efficacy of verteporfin (Visudyne® photodynamic therapy administered in conjunction with ranibizumab (Lucentis™) versus ranibizumab (Lucentis™) monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Co-investigator, 2007–2009

Natural history observation and registry for macular telangiectasia (MacTel)

Co-investigator, 2005–

Protein Kinase C β Inhibitor Study B7A-MC-MBCU. Effect of ruboxistaurin on clinically significant macular edema in patients with diabetes mellitus, as assessed by optical coherence tomography

Co-investigator, 2006–2011

Protein Kinase C β Inhibitor Study B7A-MC-MBDL. Reduction in the occurrence of center-threatening diabetic macular edema

Co-investigator, 2006–2010

Eyetech 1023: Phase IV, open label, multicenter trial of maintenance intravitreal injections of Macugen® (pegaptanib sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular age-related macular degeneration (AMD) initially treated with a modality resulting in maculopathy improvement

Co-investigator, 2006–2008

A 3-year, Phase III, multicenter, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700 µg and 350 µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in the treatment of patients with diabetic macular edema

Co-investigator, 2006–2007

A Phase IIIB, multicenter study to evaluate the safety and tolerability of ranibizumab in naïve and previously treated subjects with choroidal neovascularization secondary to age-related macular degeneration (SAILOR)

Co-investigator, 2006–2007

A 24-month randomized, double-masked, sham controlled, multicenter, phase IIIB study comparing photodynamic therapy with verteporfin (Visudyne) plus two different dose regimens of intravitreal triamcinolone acetonide (1 mg and 4 mg) versus Visudyne plus intravitreal pegaptanib (Macugen) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Co-investigator, Memphis (Tennessee) Center, 2005–2006

Other Research Activities

Leveling up equity in care for patients with diabetic eye disease: addressing navigation challenges throughout the patient journey

Scientific Collaborator, Exploratory Data Analysis, Genentech, 2025

Evaluation of hydroxychloroquine retinopathy with multifocal electroretinogram

Co-investigator, Joslin Diabetes Center, Boston MA, 2003–2004

Evaluation of patients with fifty or more years of insulin dependent diabetes mellitus

Co-investigator, Joslin Diabetes Center, Boston MA, 2003–2004

Study of genes and enzymes responsible for diabetic retinopathy

Co-investigator, Joslin Diabetes Center, Boston MA, 2003

Binocular indirect panretinal laser photocoagulation for the treatment of proliferative diabetic retinopathy: a retrospective study

Co-investigator, Retina Associates of Cleveland, 2002

Evaluation of photocoagulation for macular edema in hemi-retinal vein occlusion: a retrospective study

Co-investigator, University Hospitals of Cleveland-CWRU, 2001

Treatment of serous retinal detachments in optic nerve head pits with periocular steroids and carbonic anhydrase inhibitors: case studies

Co-investigator, Retina Associates of Cleveland, 2001

Measurement of corneal thickness changes after prolonged swimming with goggles

Medical student, Loyola Medical Center; Department of Ophthalmology,
Maywood IL, 1998

I-CAM expression on bone marrow stromal cells

Research assistant, Loyola-Stritch School of Medicine; Department of
Burn-Shock & Trauma Institute, Maywood IL, 1996

Abbott Laboratories; Department of Research & Development, North Chicago IL
Research Assistant, 1995

United States Construction Engineering Research Laboratory, Champaign IL
Environmental Research Assistant, 01/94–12/94

The Dow Chemical Company; Department of Analytical Section, Midland MI
Analytical Science Intern in X-Ray Fluorescence, 05/94–08/94

SELECTED PRESENTATIONS AT LOCAL, NATIONAL, AND INTERNATIONAL MEETINGS AND
SYMPOSIA

Lorand Johnson Lecture: A summary of Lessons Learned

Co- Moderator
Cleveland Ophthalmological Society
Cleveland, Ohio, April 2025

Every MM Matters: Slow Lesion Growth Rate with Syfovre

Moderator
Pittsburgh, PA, March 2025

A Case Based Approach to Using Vabysmo

Moderator
ARDS Annual Meeting
Aspen, CO, April 2025

Perspectives on Barriers to Ozurdex Treatment

Individual Consulting
Vit-Buckle Annual Meeting
Austin, TX, March 2025

Clinical Trial and Patient Care Case Outcomes in Wet AMD with Eylea HD

Virtual Moderator
February 2025

Clinical Trial and Patient Care Case Outcomes in Wet AMD with Eylea HD

Virtual Moderator
February 2025

Clinical Trial and Patient Case Outcomes in DME with Eylea HD

Moderator
McAllen, TX February 2025

Real GA Stories: A Treatment Journey

Moderator

Apellis Patient Webinar Program, National
December 2024

Clinical Trial and Patient Case Outcomes in Wet AMD and DME with Eylea HD

Moderator

Atlanta, GA, December 2024

Cases and Conversations: Approaching Patient Discussions and Integration of a GA Treatment into Clinical Practice

Virtual Moderator

November 2024

December 2024

Evolving Equitable Care: Taking focused action to improve outcomes for underserved patients, Genentech Health Equity Speaker Program

Moderator

Chicago, IL October 2024

Eylea HD (afibercept) Injection: Patient Cases Submission, Regeneron Commercial Advisory Board

Moderator

Chicago, IL October 2024

Genentech FutureLab+ for future STEM

Panelist

Chicago, IL October 2024

Diabetic Retinopathy: Understanding Barriers, Building Equity and Saving Vision

Axel Hanson Distinguished Lecturer NMA 2024

New York, NY August 2024

AbbVie and Regeneron ABBV-RGX-314 SR wAMD Commercial Ad Board

Moderator

Stockholm, Sweden July 2024

Illuminating Iluvien in Diabetic Macular Edema

Co-Moderator Round Table Discussion

Virtual July 2024

A Case-Based Approach to Using Vabysmo

Moderator

Kansas City, MO June 2024

Real GA Stories

Moderator

Lady Lake, Florida November 2024

Wichita, KS October 2024

Virtual, August 2024

Houston, TX June 2024

McAllen, TX June 2024

Leadership, **E**ngagement, **A**dvocacy & **P**ractice Management

American Academy of Ophthalmology Mid-Year Forum

Panelist

April 19, 2024

Syfovre (pegcetacoplan injection)

Moderator

Vermillion, OH February 2024

Boardman, OH March 2024

Syfovre (pegcetacoplan injection) GALE 1 year

Moderator

Buffalo, NY March 2024

Morgantown, WV April 2024

Real World Outcomes of the 0.19mg Fluocinolone Acetonide Implant for DME

Virtual Moderator

March 2024

When and How to Approach Using Newly Approved Anti-VEGF Agents

Roundtable Discussion

<http://eyetu.be/xehocobowi>

January 15, 2024

Diabetic Eye Disease- Understanding the Community

Optometric Retinal Update

March 7, 2023

YoungMD Connect Group at AAO

Panelist

San Francisco, CA November 2023

ASRS Health Equity Panel at AAO

San Francisco, CA November 2023

Vabysmo: The First and Only Dual-Pathway-Inhibiting Therapy in nAMD and DME

Kingsport, TN October 2023

Discussing the GA Diagnosis and Syfovre Treatment, Apellis Recording

October 2023

AJMC, Unveiling Disparities, Fostering Awareness, and Forging Inclusive Strategies in Diabetic Macular Edema Care: Insight Series
September 2023

Alimera Sciences Virtual Iluvien Roundtable discussion, Moderator
August 2023
September 2023

BMC Today Eyetube DME/AMD video Case Series
Virtual, July 2023

Elevatum Study Design and Rationale: A Phase 4 Trials of Faricimab (Vabysmo) in Underrepresented Patients with Diabetic Macular Edema
American Society of Retina Specialists Annual Meeting
Speaker
July 30, 2023

IvericBio Round Table Peer Exchange See GA Differently
Saginaw, MI, July 2023

Novartis Day of Reflection: Bridging the Health Equity Gap
Forging the Path: Advancing Healthy Equity by Addressing Disparities and Biases
Panelist
June 9, 2023

Addressing the Unmet Needs in Diabetic Macular Edema
Ohio Ophthalmological Society Annual Meeting
Technician & Nurse Education Program
Speaker
February 25, 2023

The American Journal of Managed Care Wet AMD/DME Peer Exchange
January 2023

An NEI Blindness Prevention Initiative in nAMD and RVO: Time is Vision: Early Referral/Diagnosis/Management Critical to Optimizing Patient Outcomes
Expert Panel Faculty
Prova Education
January 2023

Minority Men in Medicine Symposium
University of Maryland
Charles R Drew Pre-Health Society
Panelist
November 19, 2022

From Identification to Progression: The Consequences of Geographic Atrophy
Disease State Education
Apellis Speakers Bureau Roundtable

November 3, 2022

Congressional Black Caucus Foundation Annual Legislative Conference
Diabetic Eye Disease: Screen and Protect Your Eyes
Washington, DC
September 2022

Innovation starts with a vision: Deep dive into eye therapies~ treatments vs outcomes in DME
The College of Ophthalmology of Eastern Central and Southern Africa
Annual Scientific Conference
Malawi, Africa-Virtual
September 2022

Changing the Landscape
Speaker, American Eye Study Club
Glenden, Oregon
August 2022

American Society of Retina Specialists
OcuTerra Therapeutics OTT166
Advisory Board Faculty
July 2022

Early Identification and Timely Referral
Virtual Optometrist Speaker Program
Warren, Ohio
June 2022

Differential Response in Diabetic Macular Edema Patients
Alumni Speaker Loyola University
Chicago, Illinois
June 2022

VABYSMO: The first and Only Dual-Pathway-Inhibiting Therapy in nAMD and DME
Speaker
Flint, Michigan
April 2022
Lake Erie, Pennsylvania
May 2022
London, England
November 2022

Loyola Ophthalmology Faculty-Alumni Day
Alumni Guest Speaker
June 11, 2022

Vit-Buckle Society Annual Meeting

Moderator
Round Table Discussion
April 2022

Mid-Year Forum

Speaker
American Academy of Ophthalmology
April 2022

Diabetic Symposium

Moderator
Cleveland Ophthalmological Society
February 8, 2022

Clinical Management of Diabetic Macular Edema

Panelist
HCP Live
November 2021

Diversity, Equity and Inclusion: Perspectives from Ophthalmology Leadership

Speaker
Panelist
American Academy of Ophthalmology Symposium & NMA
November 2021

Disparities in Ophthalmologic Specialties and How this Translates to Patient Care, Big Data and Pharma

Speaker
Panelist
American Academy of Ophthalmology & NMA
November 2021

The Treatment Landscape

Presenter
Regeneron OD Speaker Program
November 2021

Non-Proliferative Diabetic Retinopathy Peer Exchange

Panelist
HCP Live
October 2021

Iluvien, Continuous Microdosing Therapy for Persistent Diabetic Macular Edema

Presenter
Alimera Speaker's Bureau
October 2021

Early Identification for Patients with Diabetic Macular Edema (DME)

Panelist

Allergan CORE Speakers' Bureau
October 2021

OCT Jeopardy
Optometric Retinal Update, Virtual Seminar
September 9, 2021

Management of secondary IOL
Speaker
Panelist
Vit-Buckle Society
April, May 2021

Understanding the Impact on Patient Lives and the Need for Timely Diagnosis and Referral
AMD/RVO Capstone Panel Discussion
Panelist
Global Learning Collaborative
February 2021

Nothing is Nothing: From Nothing to Vitrectomy Program in Haiti
Speaker
Cleveland Ophthalmological Society
February 2021

Global Ophthalmology
Moderator
Cleveland Ophthalmological Society
February 2021

Exploring the Full Scope of Ozurdex Usage in Practice
Speaker
Allergan Expert Forum
September 2020

Eye on Intraocular Pressure (IOP): Monitoring intraocular pressure when administering
Ozurdex (dexamethasone intravitreal implant) 0.7 mg
Allergan CORE Webcast
September 2020

A First- Line Treatment Option for DME and DR
Regeneron Speaker's Bureau
September 2020

Update on Diabetic Retinopathy
Optometric Retinal Update, Virtual Seminar
September 9, 2020

One Vision One Future Diversity & Inclusion Session
Genentech AIR External Council
August 2020

Maurice Rabb Presents Fluorescein Wars/Retina Emergencies Panel
Retina Symposium,
National Medical Associates, Virtual Symposium
August 2020

Cataract Surgery Prior to Silicone Oil Removal
National Medical Association, Virtual Symposium
August 2020

DARPin-New Insights in nAMD Technology
Allergan Technology Advisory Board
June 2020

Opportunities to Optimize Management of nAMD
Retina Clinical Council Advisory Board
June 2020

The New Normal: Strategies for the Management of DME in the Age of COVID & Beyond
Evolve Medical Education
May 2020

Retinal Imaging and Case Presentations
Optometric Retinal Update Seminar. Canton, Ohio
November 5, 2019

Clinical Trials for Everyday Practice
Moderator
North Canton, OH
November 2019

Efficacy and Safety of Lucentis in nAMD and DME
Speaker, Genentech GENIE Program
Allen, MI
November 2019

Breakfast Roundtable
The Atlantic Festival
Las Vegas, NV
September 26, 2019

Diagnosis and Treatment considerations for diabetic retinopathy
Speaker, Genentech Vision Expo
Las Vegas, NV
September 19, 2019

Identifying nAMD Masqueraders (T-HRT-B75602)

Novartis, REF-Speaker Program
Santa Barbara, CA
September 16, 2019

Update on Diabetic Retinopathy

Optometric Retinal Update Seminar. Beachwood, Ohio
September 12, 2019

Low-dose continuous steroid therapy for the treatment of diabetic macular edema

Moderator, Free Papers Sessions III and V
Moderator, Surgical Case Conference/Vit Buckle Society
Mediterranean Retina Meeting VIII
Dubrovnik, Croatia
August 2019

Keynote address: Diabetic retinopathy and differential treatment effect

Prevent Blindness Ohio Aging Eye Summit: Our Bodies-Our Vision
Northeast Ohio Medical University. Rootstown, Ohio
June 6, 2019

Emerging concepts and experience in the management of AMD with home monitoring

Optometric Retinal Update Seminar. Beachwood, Ohio
March 12, 2019

Diabetic retinopathy and differential treatment effect

Cleveland Ophthalmological Society. Cleveland, Ohio
February 12, 2019

OCT interpretation for the busy provider

Optometric Retinal Update Seminar. Akron, Ohio
November 1, 2018

New insights in diabetic macular edema

Consortium of Research and Education (CORE) Presentation; Vermilion, Ohio
September 19, 2018

OCT for the busy practitioner

Optometric Retinal Update Seminar. Youngstown, Ohio
August 22, 2018

Physician assistants in a retina practice

Club Vit 21st Annual Meeting; Sea Island, Georgia
June 27-30, 2018

Physician assistants in a retina practice

OIC/WAVE 2018 Conference; Vail, Colorado
June 20-23, 2018

American Academy of Ophthalmology Mid-year Forum

Washington, DC
April 20-21, 2018

Fluorescein Angiography Review Course
University Hospitals of Cleveland Ophthalmology Residents Educational Program;
Beachwood, Ohio
March 1, 2018

When to refer to retina
Eye Specialty Group/ Surgical Eye Care Foundation 13th Annual Continuing Education
Seminar; Memphis, Tennessee
February 16-18, 2018

Retina "Jeopardy"
Community Doctors Education Program; Akron, Ohio
November 7, 2017

Diabetic retinopathy and complications
Abundant Grace Fellowship Church; Cleveland Heights, Ohio
November 5, 2017

Speaker, US real-world DME data for 0.19 mg fluocinolone acetonide implant demonstrates
significant treatment burden reduction and IOP safety: USER Study
Panelist, Vit Buckle Society Surgical Case Conference
Moderator, Diabetic Retinopathy Symposium
Mediterranean Retina VII conference; Sorrento, Italy
October 12-15, 2017

Anti-inflammatory therapy for diabetic macular edema and retinal vascular occlusion
Consortium of Research and Education (CORE) Presentation; Vermilion, Ohio
September 13, 2017

Retina surgical and clinical emergencies
Community Doctors Education Program; Warren, Ohio
September 6, 2017

Clinical presentation and evaluation of autoimmune retinopathy
American Eye Study Club Meeting; Dana Point, California
August 2, 2017

Management of chronic diabetic macular edema with vitreomacular traction
Club Vit 20th Annual Meeting; Mykonos, Greece
July 2017

Invited Speaker, FedEx Custom Critical Seminar, Black History Month
Uniontown, Ohio
February 22, 2017

Anti-VEGF vs. steroids for diabetic macular edema
Management of chronic diabetic macular edema with vitreomacular traction
Management of chronic pigment epithelial detachments
Focus 2016 Medical Conference, sponsored by the American Academy of Ophthalmology
Dubai, United Arab Emirates
November 4–5, 2016

Update on the Affordable Care Act: fulfilled dreams or broken promises?
Moderator, National Medical Association Symposium
American Academy of Ophthalmology Meeting; Chicago, Illinois
October 17, 2016

Update on treatment of diabetic macular edema
Optometric Retinal Update; Youngstown, Ohio
September 7, 2016

The OASIS Trial: natural history of symptomatic vitreomacular adhesion
American Society of Retina Specialists Meeting; San Francisco, California
August 16, 2016

Update on treatment of diabetic macular edema
American Eye Study Club Meeting; Amelia Island, Florida
August 5, 2016

Diabetic retinopathy
Retinal Vascular Foundation Seminar; Cleveland, Ohio
June 11, 2016

Diabetes and diabetic retinopathy
AGF Senior Ministry Diabetes Education Forum; Cleveland, Ohio
June 11, 2016

Vitreoretinal disorders
Optometric Retinal Update; Akron, Ohio
April 6, 2016

Update on treatment of diabetic retinopathy
Optometric Retinal Update; Akron, Ohio
November 4, 2015

Vitreoretinal disorders
Optometric Retinal Update; Warren, Ohio
September 1, 2015

Moderator, Roman Barnes Distinguished Lecture and Meet the Experts panel discussion
Chairperson, Executive, Planning, and Section Business Committee meetings

Video demonstration, vitrectomy combined with Ahmed valve placement for retinal vein occlusion and neovascular glaucoma

National Medical Association Annual Convention & Scientific Assembly; Detroit, Michigan
August 1-5, 2015

The emerging role of physician assistants in vitreoretinal medicine and surgery

American Eye Study Club Meeting; Mackinac Island, Michigan
July 30, 2015

“What would you do?” case presentations and discussion

Vit-Buckle Breakfast Symposium, Vit-Buckle Society Meeting; Miami, Florida
March 20, 2015

Vitreoretinal disorders

Optometric Retinal Update; Beachwood, Ohio
March 12, 2015

Vitreoretinal diseases

Optometric Retinal Update; Warren, Ohio
September 16, 2014

Current management of vitreomacular interface disorders

National Medical Association Annual Convention & Scientific Assembly; Honolulu, Hawaii
August 2-6, 2014

First year experience with ocriplasmin

American Eye Study Club Meeting; Vail, Colorado
July 23, 2014

Early detection of macular degeneration

Perils and pitfalls of ocriplasmin/Jetrea

Panelist, Surgical Retina Symposium

Mediterranean Retina VI / Turkish Ophthalmology Society Meeting; Izmir, Turkey
June 2014

Screening and early detection of age-related macular degeneration

Update on treatments for retinal diseases

Optometric Retinal Update; New Castle, Pennsylvania
December 4, 2013

Retina case presentations

Optometric Retinal Update; Beachwood, Ohio
September 10, 2013

Patient selection for ocriplasmin

American Eye Study Club Annual Meeting; Atlantis Resort, Paradise Island, Bahamas
August 2, 2013

Update on treatments for retinal diseases

Optometric Retinal Update; Beachwood, Ohio

March 14, 2013

Guest Speaker

Black History Month Program, Jefferson Elementary School, Warren, Ohio

February 4, 2013

Retinal update on anti-VEGF therapy (with Dr.'s Miller, Novak, Rao, Schartman, and Zegarra)

Ophthalmologists' Update Seminar. Vermilion, Ohio

December 20, 2012

Unilateral progressive hyperopia

Mayo Clinic Retina Update and Case Conference, Rochester, Minnesota

September 21, 2012

Safety and efficacy of ranibizumab treatment for diabetic macular edema

Optometric Retinal Update; Youngstown, Ohio

September 20, 2012

Retinal update on anti-VEGF therapy (with Drs. Miller, Novak, Rao, Schartman, and Zegarra)

Ophthalmologists' Update Seminar. Vermilion, Ohio

Co-Moderator

August 12, 2012

Panelist, Where's the evidence? Review of the Comparisons of Age-related Macular Degeneration Trials (CATT): A comparison of Lucentis and Avastin for the treatment of wet age-related macular degeneration (AMD)

National Medical Association Annual Meeting; New Orleans, Louisiana

Co-Moderator, Retina Symposium

July 30, 2012

Genetic testing and macular degeneration

American Eye Study Club Annual Meeting; The Grand Del Mar Resort, San Diego, California

August 1, 2012

Surgical management of epiretinal membranes

5th Mediterranean Retina Meeting and 16th Afro-Asian Congress of Ophthalmology; Istanbul, Turkey

June 16, 2012

Surgical management of epiretinal membranes

Optometric Retinal Update; Beachwood, Ohio

March 15, 2012

Hereditary retinal disorders: Newly diagnosed, now what?

Foundation Fighting Blindness, Cleveland Leadership Call Speaker Series; Cleveland, Ohio
December 3, 2011

Moderator, Retina Symposium

Speaker, 1) Epiretinal membranes; 2) Chronic central serous chorioidopathy.
Croatian Ophthalmological Society; Dubrovnik, Croatia
October 2011

Assessment and management of epiretinal membranes

Optometric Retinal Update; Youngstown, Ohio
September 1, 2011

Photodynamic therapy with Visudyne for central serous chorioretinopathy

American Eye Study Club 54th Annual Meeting – Summer Conference; Pinehurst, North
Carolina
July 27, 2011

Moderator, Retina Symposium

Contributor, Surgical Symposium: Small gauge sutureless surgery for complicated retinal
diseases

National Medical Association Annual Convention and Scientific Assembly; Washington, DC
July 26, 2011

Emerging treatments for diabetic retinopathy

Optometric Retinal Update; Beachwood, Ohio
March 3, 2011

Retina Symposium Moderator

National Medical Association Annual Convention and Scientific Assembly; Orlando,
Florida
August 1, 2010

Brown CC, Coney JM, H. Zegarra H. Results of photodynamic therapy with verteporfin for
the treatment of central serous chorioretinopathy.

Rabb Venable Research Competition
August 1, 2010

Update on diabetic retinopathy

Optometric Retinal Update; New Castle, Pennsylvania
May 13, 2010

Singerman LJ, Novak MA, Miller DG, Coney JM, et al. Ranibizumab treatment for pigment
epithelial detachment (PED) in age-related macular degeneration (AMD).

Retina Congress 2009, Combined Meeting of the American Society of Retina Specialists,
The Macula Society, and The Retina Society; New York, New York
September 30–October 4, 2009

Neovascular peripheral retinal disease

Optometric Retinal Update; Youngstown, Ohio
August 20, 2009

Retina surgery videos (with David G. Miller, MD)
National Medical Association Annual Meeting; Las Vegas, Nevada
July 25–29, 2009

Berlon NR, Miller DG, Novak MA, Pendergast SD, Coney JC. Safety and efficacy of 25-gauge vitrectomy surgery by experienced vitreoretinal surgeons.
Association for Research in Vision and Ophthalmology Annual Meeting. Program # 5202; Fort Lauderdale, Florida.
May 7, 2009

Diabetes and the eye
Cleveland Ophthalmic Personnel Society; Independence, Ohio
April 19, 2009

Surgical techniques for epiretinal membrane removal
Retinal Update for Ophthalmologists; Youngstown, Ohio
March 18, 2009

Photodynamic therapy for central serous chorioretinopathy
Cleveland Ophthalmological Society; Cleveland, Ohio
February 10, 2009

Posterior complications of anterior segment surgery
Optometric Retinal Update; Youngstown, Ohio
September 18, 2008

Posterior complications of anterior segment surgery
National Medical Association Annual Meeting; Atlanta, Georgia
July 2008

Open forum presentation, Eye Care America; glaucoma screening booth
Cleveland Medical Association Radio One Health Fair
April 27 & 28, 2008

Newest information on research and treatments for macular degeneration
Macula Vision Research Foundation SupportSight Seminar, Middleburg Hts, Ohio
April 8, 2008

Diabetic retinopathy
Optometric Retinal Update; New Castle, Pennsylvania
October 25, 2007

Update on management of macular edema

Optometric Retinal Update; Youngstown, Ohio
September 5, 2007

Rabb-Venable Fluorescein Angiography Conference
National Medical Association Annual Meeting; Waikiki, Hawaii
August 2007

Optic nerve head pits
Cleveland Ophthalmological Society; Cleveland, Ohio
April 10, 2007

Answers to the top 10 questions about macular degeneration
▪ Macula Vision Research Foundation SupportSight Seminar; Middleburg Hts, Ohio
March 24, 2007

Complications of diabetic retinopathy
First Annual Chairman's Research Forum, Diabetes Association of Greater Cleveland;
Union Club, Cleveland, Ohio
Invited Speaker; November 2, 2006

Macular degeneration: causes, copings and cures
Weils Community Event; Chagrin Falls, Ohio
Invited Speaker; October 10, 2006

Grading diabetic retinopathy
Optometric Retinal Update; Beachwood, Ohio
September 28, 2006

Grading diabetic retinopathy
Optometric Retinal Update; Youngstown, Ohio
September 25, 2006

Ophthalmology and systemic diseases: utility of ophthalmologic input for diagnostic and
therapeutic purposes
Southwest Hospital Grand Rounds (CME credit course); Middleburg Hts, Ohio
July 28, 2006

Clinical characteristics of complications in patients with 50 or more years of Type 1 diabetes
National Medical Association 109th Annual Scientific Section; San Diego, California
August 2004

Management of serous retinal detachments
Aravind Eye Hospital, Department of Ophthalmology; Maduri, India
June 2004

Clinical grading of diabetic retinopathy lecture series/conference
Aravind Eye Hospital, Department of Ophthalmology; Maduri, India
May 2004
Massachusetts Eye & Ear Infirmary Resident Teaching; Boston, Massachusetts 2003–
2004

Evaluation of photocoagulation for macular edema in hemi-retinal vein occlusion: a retrospective study

Aravind Eye Hospital, Department of Ophthalmology; Maduri, India

May 2004

Case Western Reserve University Ninth Annual Resident and Alumni Research Day;
Cleveland, Ohio

June 2002

Optic nerve pits: the origin and management of serous retinal detachments

Longwood Medical Association of Ophthalmology/Harvard Medical School; Boston,
Massachusetts

October 2003

University Hospitals of Cleveland, Department of Ophthalmology, Grand Rounds
Cleveland, Ohio

June 2003

Binocular indirect panretinal laser photocoagulation for the treatment of proliferative diabetic retinopathy: a retrospective study

Aravind Eye Hospital, Department of Ophthalmology; Maduri, India

May 2004

American Society of Retina Specialists 21st Annual Meeting New York, New York

August 2003

National Medical Association 108th Annual Scientific Section; Philadelphia, Pennsylvania
August 2003

Case Western Reserve University Ninth Annual Resident and Alumni Research Day;
Cleveland, Ohio

June 2003

Angioid streaks: the management of CNVM

Case Western Reserve University Second Annual Residents Day; Cleveland, Ohio

March 2003

Current management of idiopathic parafoveal telangiectasis

Case Western Reserve University Second Annual Residents Day; Cleveland, Ohio

March 2003

Diagnosis & management of idiopathic polypoidal choroidopathy

University Hospitals of Cleveland, Department of Ophthalmology, Grand Rounds;
Cleveland, Ohio

February 2003

Ocular manifestations of sarcoidosis

Case Western Reserve University First Annual Residents Day; Cleveland, Ohio

November 2001

MANUSCRIPTS

1. Review of AJO-20-1827, "The Impact of Race on Short Term Treatment Response to Bevacizumab in Diabetic Macular Edema"

ONLINE PUBLICATIONS

1. <https://blackdoctor.org/why-eye-screenings-are-a-must-for-black-diabetics/>
2. <https://bdopro.com/ophthalmology/diabetic-retinopathy-black-patients/>
3. Voices of Unity: Eye doctor helps students achieve their dreams.
<https://fox8.com/news/voices-of-unity/voices-of-unity-eye-doctor-helps-students-achieve-their-dreams/>
4. “Open Your Eyes” Blackdoctor.org Monthly Diabetic Eye Care Series Podcast. Six-Monthly Podcasts on Diabetic Eye Disease, 2022-

Part 1

Know Your Risk for Diabetic Related Eye Disease May 19,
2022
The Importance of Regular Eye Care June
15, 2022
The Importance of Self Advocacy July 11,
2022
Overcoming the Obstacles of Diabetic Retinopathy (It’s Not Just Sugar) August 26,
2022
Double Danger: Diabetic Retinopathy & Glaucoma September
21, 2022
Improved Care Through Shared Decision Making
November 28, 2022

Part 2

Understanding Diabetic Retinopathy
June 7, 2023

5. Vision RELIEF: Diversity, Equity and Inclusion in Ophthalmology, recorded educational series
6. Marwan Abdulaal, Joseph Coney, MD, Vuity, Eyewiki, June 2022
7. The Art of Drug Choice online video recording,
8. Ryan Zubricky, Marwan Abdulaal, MD, Joseph Coney, MD: Brolucizumab, *Eyewiki*, August 2021
9. Wykoff CC, Kiss S, Coney JM, Chiang A, Bauman CR; Diabetic Retinopathy: Changing Treatment Paradigms. Is there a role for the medical management of NPDR? Part Two of Two. *Retina Today* (Digital supplement). January/February 2019.
<https://supplements.retinatoday.com/articles/diabetic-retinopathy-changing-treatment-paradigms/diabetic-retinopathy-changing-treatment-paradigms-2/?single=true>.
10. Laser versus anti-VEGF treatment for diabetic patients. February 2018.

<https://eyetube.net/series/diabetic-retinopathy/wgpow/>

11. Early wet AMD detection with ForeseeHome. February 2018. <https://www.opthalmologymanagement.com/videos/early-wet-amd-detection-with-foreseehome>
12. Fellowship training in Haiti: A training program in Port-au-Prince brings retina education to an area of need. *New Retina MD*, December 2017. <http://nrmdonline.com/2017/12/fellowship-training-in-haiti/>
13. Diabetes can destroy your eyesight. *CODE M Magazine*, August 2017. <http://codemediagroupllc.com/>
14. Black History Month Feature: Doctor uses doubts of others to become one of best in country. Fox8 News, Cleveland, Ohio; February 3, 2017. <http://fox8.com/2017/02/03/black-history-month-doctor-uses-doubts-of-others-to-become-one-of-best-in-country/>
15. Dr. Joseph M. Coney provides retina surgery training to ophthalmologists in Haiti. <https://www.usretina.com/2016/07/07/dr-joseph-m-coney-provides-retina-surgery-training-to-ophthalmologists-in-haiti/>
16. A new & novel approach: incorporating certified physician assistants into your practice. Interview with Nicole Sheeler, *RetinaLink*, July 10, 2015. <http://retinalinkglobal.com/a-new-novel-approach-incorporating-certified-physician-assistants-into-your-practice/>

PUBLICATIONS

Journal Articles

1. Joseph Coney; Paul Hahn; Ehsan Rahimy; Prya Vakharia. Expert Spotlight: A Closer Look at Geographic Atrophy Treatment, Sponsored by Apellis Pharmaceuticals, Inc. *Ocular Surgery News*, APR 16, 2024
2. Coney JM, McCoy JE, Buxy Sinha S, Sonbolian N, Zhou L, Hull TP, Lewis SA, Miller DG, Novak MA, Pendergast SD, Pham H, Platt SM, Rao LJ, Schartman JP, Singerman LJ, Donkor R, Fink M, Zubricky R, Karcher H. One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents. *Clin Ophthalmol*. 2023;17:3601-3611 <https://doi.org/10.2147/OPTH.S432957>
3. Abdulaal, Marwan; Donkor, Richard; Roberston, Jacobi; Lewis, Shawn; Miller, David; Schartman, Jerome; Platt, Sean; Coney, Joseph. Rapid Surgical Displacement of Submacular Hemorrhage without Tissue Plasminogen Activator Use: One-year Outcomes. *Canadian Journal of Ophthalmology* (Ahead of Print 2023).
4. Zubricky, R., McCoy, J., Donkor, R. *et al*. Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab. *Ophthalmol Ther* (2023). <https://doi.org/10.1007/s40123-40>

[023-00741-w](#)

5. Coney JM, Zubricky R, Sinha SB, Sonbolian N, Zhou L, Hull TP, Lewis SA, Miller DG, Novak MA, Pendergast SD, Pham H, Platt SM, Rao LJ, Schartman JP, Singerman LJ, Donkor R, Fink M, McCoy J, Karcher H. Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration. *Int J Retina Vitreous*. 2023 Feb 1;9(1):8. doi: 10.1186/s40942-023-00445-0. PMID: 36726178; PMCID: PMC9891747.
6. Bumal CR, Berrocal AM, Berrocal MH, Chan RVP, Coney JM, Lalwani G, Regillo CD. How to Mentor Tomorrow's Retina Leaders, *Retina Today*/March 2022
7. Coney JM, Scott AW. Racial disparities in the screening and treatment of diabetic retinopathy. *J Natl Med Assoc*. 2022 Jan 29:S0027-9684(21)00236-4. doi: 10.1016/j.jnma.2021.12.011. Epub ahead of print. PMID: 35105457.
8. Ryan Zubricky, Marwan Abdulaal, MD, Joseph Coney, MD: Brolucizumab, *Eyewiki*, August 2021
9. Oliver M, Williams B, Coney JM, Miller-Ellis, E: Improving Diversity in the Field of Retina, *Retinal Physician*, July/August 2021
10. Coney, JM. Racial Bias in Clinical Trials: What You Need to Know. *Retina Times*. March, 2021, 46-48.
11. Abdulaal M, Robertson JA, Moore MT, Coney JM. Risk and Assessment of COVID-19 in a Retina Ophthalmologic Setting. *Clin J Ophthalmol Care Res*. 2021; 3: 1006.
12. Coney, JM. Walking by Faith to Help Restore Sight: Dr. Joseph M .Coney, *Career & Lifestyle Magazine*, June 2020
13. Lakhanpal RR , Cone JM, Iridodialysis Suture Lens Case Study, *Retina Today, meeting minutes, VBS at Mediterranean Retina*, January February 2020
14. Coney JM. Addressing unmet needs in diabetic retinopathy. Greater adherence to eye screening guidelines among patients with diabetes is required to facilitate prompt diagnosis and early treatment of DR. It is important for policy makers to keep this in mind to reinforce best practices among clinicians who should stay up to date with screening recommendations and be aware of patient-level barriers to ophthalmic care. *The American Journal of Managed Care (supplement)* October 2019, Vol 25. No. 16, S311-S316, www.ajmc.com.
15. Singer MA, Coney JM, Blinder KJ, Sanders RJ. Ozurdex (dexamethasone intravitreal implant) 0.7 mg as initial therapy in pseudophakic patients with diabetic macular edema, macular edema following retinal vein occlusion, and noninfectious posterior segment uveitis: a case-based approach. *Retina, the Journal of Retina and Vitreous Diseases* (supplement). June 2019.
16. Khanani AM, Gahn GM, Markoff J, Khalaf H, Gonzalez VH, Coney JM, Fineman MS, Haller JA. Full-thickness macular hole and symptomatic vitreomacular adhesion:

- comparison of visual results in patients receiving pars plana vitrectomy in one eye and ocriplasmin in the fellow eye. *Journal of VitreoRetinal Diseases* (in press)
<https://doi.org/10.1177/2474126419866141>.
17. Coney JM. Fluocinolone acetonide 0.19 mg intravitreal implant improves foveal thickness and reduces treatment burden for up to 1 year in eyes with persistent diabetic macular edema. *International Medical Case Reports Journal*. 2019;12:161–169.
 18. Chew EY, Clemons TE, Jaffe GJ, Johnson CA, Farsiu S, Lad EM, Guymer R, Rosenfeld P, Hubschman JP, Constable I, Wiley H, Singerman LJ, Gillies M, Comer G, Blodi B, Elliott D, Yan J, Bird A, Friedlander M; Macular Telangiectasia Type 2-Phase 2 CNTF Research Group. Effect of ciliary neurotrophic factor on retinal neurodegeneration in patients with macular telangiectasia type 2: a randomized clinical trial. *Ophthalmology*. 2019;126:540-549.
 19. Yu JJ, Agrón E, Clemons TE, Domalpally A, van Asten F, Keenan TD, Cukras C, Chew EY; Age-Related Eye Disease Study 2 Research Group. Natural History of Drusenoid Pigment Epithelial Detachment Associated with Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report No. 17. *Ophthalmology*. 2019;126:261-273.
 20. Keenan TD, Agrón E, Domalpally A, Clemons TE, van Asten F, Wong WT, Danis RG, Sadda S, Rosenfeld PJ, Klein ML, Ratnapriya R, Swaroop A, Ferris FL 3rd, Chew EY; AREDS2 Research Group. Progression of geographic atrophy in age-related macular degeneration: AREDS2 Report Number 16. *Ophthalmology*. 2018;125:1913-1928.
 21. Jampol LM, Glassman AR, Liu D, Aiello LP, Bressler NM, Duh EJ, Quaggin S, Wells JA, Wykoff CC; Diabetic Retinopathy Clinical Research Network. Plasma vascular endothelial growth factor concentrations after intravitreal anti-vascular endothelial growth factor therapy for diabetic macular edema. *Ophthalmology*. 2018;125:1054-1063.
 22. Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the second year of the Comparison of Age-Related Macular Degeneration Treatments Trials. *Ophthalmology*. 2016;123:865-875.
 23. Shah N, Maguire MG, Martin DF, Shaffer J, Ying GS, Grunwald JE, Toth CA, Jaffe GJ, Daniel E; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Angiographic cystoid macular edema and outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. *Ophthalmology*. 2016;123:858-864.
 24. AREDS2 Research Group, Al-Holou SN, Tucker WR, Agrón E, Clemons TE, Sperduto RD, Ferris FL 3rd, Chew EY. The association of statin use with cataract progression and cataract surgery: The AREDS2 Report Number 8. *Ophthalmology*. 2016;123:916-917.
 25. Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). *Ophthalmology*. 2016;123:609-616.

26. Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL 3rd, Flaxel CJ, Friedman SM, Glassman AR, Jampol LM, Rauser ME; Diabetic Retinopathy Clinical Research Network. Persistent macular thickening after ranibizumab treatment. *JAMA Ophthalmol.* 2016;134:278-285.
27. Wells JA, Glassman AR, Jampol LM, Aiello LP, et al; Diabetic Retinopathy Clinical Research Network. Association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. *JAMA Ophthalmol.* 2016;134:127-134.
28. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, Baker CW, Berger BB, Bressler NM, Browning D, Elman MJ, Ferris FL 3rd, Friedman SM, Marcus DM, Melia M, Stockdale CR, Sun JK, Beck RW. Panretinal photocoagulation vs intravitreal ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. *JAMA.* 2015 Nov 13:1-11.
29. Aref AA, Scott IU, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC; SCORE Study Investigator Group. Incidence, risk factors, and timing of elevated intraocular pressure after intravitreal triamcinolone acetonide injection for macular edema secondary to retinal vein occlusion: SCORE Study Report 15. *JAMA Ophthalmol.* 2015 Sep;133:1022-1029.
30. Aiello LP, Ayala AR, Antoszyk AN, Arnold-Bush B, Baker C, Bressler NM, Elman MJ, Glassman AR, Jampol LM, Melia M, Nielsen J, Wolpert HA; Diabetic Retinopathy Clinical Research Network. Assessing the effect of personalized diabetes risk assessments during ophthalmologic visits on glycemic control: a randomized clinical trial. *JAMA Ophthalmol.* 2015;133:888-896.
31. Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, Daniel E, Jaffe GJ; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Subretinal hyperreflective material in the Comparison of Age-Related Macular Degeneration Treatments Trials. *Ophthalmology* 2015;122:1846-1853.
32. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *N Engl J Med* 2015 Mar 26;372:1193-1203.
33. Friedman SM(1), Almukhtar TH, Baker CW, Glassman AR, Elman MJ, Bressler NM, Maker MP, Jampol LM, Melia M; Diabetic Retinopathy Clinical Research Network. Topical nepafenec in eyes with noncentral diabetic macular edema. *Retina* 2015;35:944-956.
34. Chew EY, Clemons TE, Peto T, Sallo FB, Ingerman A, Tao W, Singerman L, Schwartz SD, Peachey NS, Bird AC; MacTel-CNTF Research Group. Ciliary neurotrophic factor (CNTF) for macular telangiectasia Type 2 (MacTel): Results from a phase I safety trial. *Am J Ophthalmol* 2015;159:659-666.
35. Altaweel MM, Daniel E, Martin DF, Mittra RA, Grunwald JE, Lai MM, Melamud A, et al; Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials (CATT)

- Research Group. Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). *Ophthalmology* 2015;122:391-398.
36. Folgar FA, Jaffe GJ, Ying GS, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials. *Ophthalmology* 2014;121:1956-1965.
37. Kim BJ, Ying GS, Huang J, Levy NE, Maguire MG; CATT Research Group. Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). *Am J Ophthalmol* 2014;158:128-135.
38. Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). *JAMA Ophthalmol* 2014;132:521-527.
39. Rao LJ, Coney JM, Schartman JP, Singerman, LJ. Neovascular AMD: treatment beyond anti-VEGF. *Retinal Physician* 2014;11:23-28.
40. Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, Grover S, Miller DG; Diabetic Retinopathy Clinical Research Network. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. *JAMA Ophthalmol* 2013;131:1033-1040.
41. Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, Grunwald JE, Huang J; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. *Ophthalmology* 2013;120:1860-1870.
42. Danis RP, Domalpally A, Chew EY, Clemons TE, Armstrong J, SanGiovanni JP, Ferris FL 3rd; AREDS2 Study Group. Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2). *Invest Ophthalmol Vis Sci* 2013 8;54:4548-4554.
43. Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG, Kim IK, Klein ML, Maguire MG, Martin DF; Comparison of AMD Treatments Trials Research Group. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). *Ophthalmology* 2013;120:593-599.
44. Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. *JAMA Ophthalmol* 2013;131:283-293.
45. Ying GS, Huang J, Maguire MG, et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.

Ophthalmology 2013 Jan;120:122-129.

46. Diabetic Retinopathy Clinical Research Network, Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL 3rd, Glassman AR, Maturi RK, Melia M. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. *Ophthalmology* 2012;119:2312-2318.
47. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. *Ophthalmology* 2012;119:1388-1398.
48. Schartman JP, Coney JM, Hornik JH, Miller DG. Pegaptanib octasodium for the treatment of diabetic macular oedema. *Expert Opinion on Pharmacotherapy* 2011;12:1317-1323.
49. Gangaputra S, Almukhtar T, Glassman AR, Aiello LP, Bressler N, Bressler SB, Danis RP, Davis MD; Diabetic Retinopathy Clinical Research Network. Comparison of film and digital fundus photographs in eyes of individuals with diabetes mellitus. *Invest Ophthalmol Vis Sci* 2011;52:6168-6173.
50. Chan CK, Ip MS, VanVeldhuisen PC, Oden NL, Scott IU, Tolentino MJ, Blodi BA; SCORE Study Investigator Group. SCORE Study Report #11. Incidences of neovascular events in eyes with retinal vein occlusion. *Ophthalmology* 2011;118:1364-1372.
51. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration.. *N Engl J Med*. 2011 May 19;364:1897-1908. Epub 2011 Apr 28.
52. Coney JM, Schartman JP, Singerman LJ. Advancing treatments for diabetic macular edema. *Retinal Physician* 2011;8:40, 43-44, 46.
53. Diabetic Retinopathy Clinical Research Network; Writing Committee, Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology* 2011;118:609-614.
54. Flaxel CJ, Edwards AR, Aiello LP, Arrigg PG, Beck RW, Bressler NM, Bressler SB, Ferris FL 3rd, Gupta SK, Haller JA, Lazarus HS, Qin H. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: Diabetic Retinopathy Clinical Research Network. *Retina* 2010;30:1488-1495.
55. Coney JM, Miller DG. Epiretinal membrane. *Focal Points*. Volume XXVII, Number 5, American Academy of Ophthalmology, 2009.
56. Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Antoszyk AN; SCORE Study Investigator Group. SCORE Study Report 7: incidence of intravitreal silicone oil droplets

- associated with staked-on vs luer cone syringe design. *Am J Ophthalmol* 2009;148:725-732.
57. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. *Arch Ophthalmol* 2009;127:1115-1128.
 58. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. *Arch Ophthalmol* 2009;127:1101-1114.
 59. Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Figueroa M, Antoszyk A, Elman M and the SCORE Study Investigator Group. SCORE Study Report 3: Study design and baseline characteristics. *Ophthalmology* 2009;116:1770-1777.
 60. Patronas M, Coney JM, Singerman LJ. Treating neovascular peripheral retinal diseases. *Retinal Physician* 2008;5(8):53,54,56,58.
 61. Coney JM, Novak MA, Zegarra H. New treatments for diabetic macular edema. *MD News* 2008; 12 (2):32, 34.
 62. Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H; Diabetic Retinopathy Clinical Research Network. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. *Ophthalmology* 2008;115:1366-1371, 1371.e1.
 63. Coney JM, Singerman LJ. Patient management in intravitreal injections. *Retinal Physician* 2007;4:52,55.
 64. Keenan HA, Costacou T, Doria A, Coney JM, Orchard TJ, Aiello LP, King GL. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the fifty-year medalist study. *Diabetes Care* 2007;30:1995-1997.
 65. Jager RI, Timothy NH, Coney JM, Katalinic P, Cavicchi RW, Strong J, Cavallerano JD, Aiello LP. Congenital retinal macrovessel. *Retina, The Journal of Retinal and Vitreous Diseases* 2005;25:538-540.
 66. Gurelik G, Coney JM, Zakov ZN. Binocular indirect panretinal laser photocoagulation for the treatment of proliferative diabetic retinopathy: a retrospective study. *Ophthalmic Surg Lasers Imaging* 2004;35:94-102.
 67. Kopstein A, Coney J, Bouchard CS. Corneal pachymetric and biomicroscopic changes after swimming with and without goggles: A prospective study. *Invest Ophthalmol Vis Sci* 1999;39:S913.

Abstracts/Posters

1. Brown, David; Wykoff, Charles; Coney, Joseph; Jonisch, Jonathan; Kim, Esther; Lally,

- David; Sadda, Srinivas; Lin, Jason; Tsuboi, Min; Maumal, Caroline R.; Boyer, David. Pegcetacoplan in Sham Eyes that Crossed Over to Active Pegcetacoplan Treatment in Geographic Atrophy due to AMD: 12-Month GALE Results. American Society of Retina Specialists Annual Meeting, July 2024.
2. Miller, Alexander; Sciulli, Harrison; Coney, Joseph; Hull, Thomas; Lewis, Shawn; Nothnagel, Arnold; Novak, Michael; Pendergast, Scott; Pham, Hang; Platt, Sean; Rao, Llewelyn; Schartman, Jerome; Singerman, Lawrence; Wilker, Shawn; Goduni, Ledian; Tsai, Thomas; Miller, David. Early Real-World Experience with Pegcetacoplan (Syfovre™) in a Large Retinal Practice. American Society of Retina Specialists Annual Meeting, July 2024.
 3. Ziccardi, Z., Hanna, J., Sciulli, H., Miller, D., Coney, J., Rao, L. Efficacy of Faricimab-svoa on Visual Acuity and Central Subfield Thickness in post Pars Plana Vitrectomy eyes with Neovascular Macular Degeneration. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, May 2024.
 4. Sciulli, H., Miller, C., Coney, J., Goduni, L., Hull, T., Lewis, S., Nothnagel, N., Novak, M., Pendergast, S., Pham, H., Platt, S., Rao, L., Schartman, J., Singerman, L., Tsai, T., Wilker, S., Miller, D. Utilization of Intraocular Dexamethasone Implant 0.7mg in a Large Retina Practice. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, May 2024.
 5. Cunninham M., Coney J., Williams Scott A., Amador M., Chang J., Stoilov I., Meldorf M., Gonzalez L. ELEVATUM Study Design and Rational: A Phase 4 Trial of Faricimab (Vabysmo) in Underrepresented Patients with DME. Abstract, American Society of Retina Specialists Annual Meeting, July 2023.
 6. Godel S., Oncel D., Donkor R., Coney J. M. Real-world clinical outcomes after sustained delivery of the 0.19 mg fluocinolone acetonide (FAc) implant for treatment of diabetic macular edema (DME). Poster, Association for Research in Vision and Ophthalmology Annual Meeting, April 2023.
 7. Zubricky R., McCoy J., Sinha S. B., Sobolian N., Zhou L., Donkor R., McCrossin C., Miller D., Pham H., Schartman J., Rao L., Singerman L., Novak M., Pendergast S., Karcher H., Coney J. Injection intervals in real-world neovascular age-related macular degeneration (nAMD) patients switch to brolucizumab with at least 12 months of follow-up. Poster, Association for Research in Vision and Ophthalmology Annual Meeting, May 2022.
 8. McCoy J., Zubricky R., Sinha S. B., Sobolian N., Zhou L., Donkor R., McCrossin C., Miller D., Pham H., Schartman J., Rao L., Singerman L., Novak M., Pendergast S., Karcher H., Coney J. Characterization of real-world neovascular age-related macular degeneration (nAMD) switch patients treated with brolucizumab (BROL) alternating with other anti-Vascular Endothelial Growth Factors (VEGF) versus brolucizumab alone. Poster, Association for Research in Vision and Ophthalmology Annual Meeting, May 2022.
 9. Marwan Abdulaal, Jacobi Robertson, Madison T. Moore, Joseph M. Coney. Subretinal

Pneumatic Displacement without Tissue Plasminogen Activator for Submacular Hemorrhage: One-year Outcomes. Abstract, American Eye Study Club, August 2022

10. Abdulaal, Marwan; Miller, David G.; Platt, Sean M.; Coney, Joseph M.; One year follow up of The Surgical Management of Submacular Hemorrhage with Subretinal Balanced Saline Solution and Pneumatic Displacement. Poster, Association for Research in Vision and Ophthalmology Annual Meeting. May 2021.
11. Robertson, Jacobi A.; Abdulaal, Marwan; Moore, Madison T.; Coney, Joseph M.; Platt, Sean; Rao, Llewelyn J.; Miller, David G.; Pendergast, Scott D.; Schartman, Jerome P. Risk and Assessment of COVID-19 in a Retina Ophthalmic Setting. Poster, Association for Research in Vision and Ophthalmology Annual Meeting. May 2021.
12. Yalamanchili S, Rao L, Rowland D, Gonzalez C, Miller D, Novak M, Pendergast S, Coney J, Schartman J, Lewis S. Comparative Success of Retinal detachment Repair among Private Practice Surgeons. The American Society of Retina Specialists, July 2019
13. Daroszewski D, Coney J, Schartman J, Miller D, Rao L, Zegarra H. Efficacy of the 0.19 mg fluocinolone acetonide (FAc) 4 (Iluvien®) in a multiphysician, single-practice setting – the Cleveland experience. Poster B0155, Association for Research in Vision and Ophthalmology Annual Meeting. Vancouver, British Columbia, Canada, April-May 2019.
14. Chandra C, Pophal C, Miller A, Hornik J, Schartman J, Coney J, Singerman L, David D. Efficacy of macular hole surgery in patients with idiopathic macular telangiectasia Type 2. Scientific Poster A0222, Association for Research in Vision and Ophthalmology Annual Meeting. Vancouver, British Columbia, Canada, April-May 2019.
15. Pophal C, Chandra R, Hornik J, Miller D, Singerman L, Zegarra H, Novak M, Pendergast S, Coney J, Rao L, Zakov ZN, Schartman J. Surgical outcomes and patient satisfaction in vitrectomy for vitreous floaters. Scientific Poster A0228, Association for Research in Vision and Ophthalmology Annual Meeting, April-May 2019.
16. Liu J, Coney J, Schartman J, Miller DG, Zegarra H, Rao L. Fluocinolone acetonide (FAc) 0.2 mg intravitreal implant in the treatment of diabetic macular edema (DME).
 - Poster 4816 - C0174, Association for Research in Vision and Ophthalmology Annual Meeting. Honolulu, Hawaii, May 2018.
 - Best PGY-3 Resident VSRC Research Presentation, University Hospitals Ophthalmology Residents Research Day Symposium, June 2018.
17. Rostamizadeh M, Abdelaziz M, Patel A, Moarefi M, Miller D, Coney J, Novak M, Rao L, Pendergast S, Singerman L. Incidence of endophthalmitis in various anti-VEGF treatments. Poster 5025/ B0231, Association for Research in Vision and Ophthalmology Annual Meeting. Seattle, Washington, May 2016.
18. O'Neill B, Shah A, Coney JM. Resolution of vitreomacular traction using Jetrea and its potential role in diabetic macular edema. Poster 294/B0272. Association for Research in

Vision and Ophthalmology Annual Meeting. Orlando, Florida, May 2014.

19. Singerman LJ, Himmelman DR, Singerman B, Thomas A, Newman L, Coney JM, Schartman JP, Novak MA. Impact of Lucentis on psychological morbidity in patients with macular edema and neovascularization secondary to retinal vein occlusion. Poster 5466/A662. Association for Research in Vision and Ophthalmology Annual Meeting. Fort Lauderdale, Florida, May 2012.
20. Brown CC, Coney JM, Zegarra H. Results of photodynamic therapy with verteporfin for the treatment of central serous chorioretinopathy. Association for Research in Vision and Ophthalmology Annual Meeting. Program # 1341 / Poster #A354. Fort Lauderdale, Florida. May 3, 2010.
21. Clinical characteristics of complications in patients with 50 or more years of Type 1 diabetes; American Diabetes Association 64th Annual Scientific Section. Orlando, Florida; June 2004.
22. Evaluation of insulin dependent diabetic patients with more than fifty years of diabetes. Association for Research in Vision and Ophthalmology. Fort Lauderdale, Florida; April 2004.
23. Endophthalmitis as a complication of intravitreal injection: a systemic review. Association for Research in Vision and Ophthalmology. Fort Lauderdale, Florida; April 2004.
24. Evaluation of photocoagulation for macular edema in hemi-retinal vein occlusion: a retrospective study. Association for Research in Vision and Ophthalmology Fort Lauderdale, Florida; May 2002.
25. Binocular indirect panretinal laser photocoagulation for the treatment of proliferative diabetic retinopathy: a retrospective study
 - Retina Society 36th Scientific Session; Chicago, Illinois; September 2003
 - Association for Research in Vision and Ophthalmology; Fort Lauderdale, Florida; May 2003.
26. Measurement of corneal thickness changes after prolonged swimming with goggles. Association for Research in Vision and Ophthalmology; Fort Lauderdale, Florida; March 1999.
27. I-CAM expression on bone marrow stromal cells
 - National Medical Research Forum; Galveston, Texas; April 1997.
 - Student National Medical Association & National Institutes of Health; New Orleans, Louisiana; March 1997.
 - Midwest Student Medical Research Forum; Omaha, Nebraska; February 1997.
 - St. Luke's Research Forum, Loyola-Stritch School of Medicine; Maywood, Illinois; October 1996.

VIDEO RECORDINGS

1. DME/AMD BMC video
2. Syfovre, <https://syfovrecp.com/educational-videos/>

3. BMC DME/AMD video case series
4. Broaching the Topic of a Retinal Specialist With Your Patients With Diabetes
5. Novartis D&I in Clinical Trials Video
6. Vison RELIEF